Amino Medical Science

What Amino Medical Science does

Amino Medical Science is a privately held, clinical-stage biotechnology company developing a portfolio of small molecule therapeutics for multifactorial metabolic diseases. It is incorporated in Delaware with a registered office in Lewes and operates with 11–50 employees. The company's product candidates target indications with limited or no FDA-approved therapies, including heart failure with preserved ejection fraction (HFpEF), cancer cachexia, obesity, fatty liver disease (alcoholic fatty liver and NASH), and pediatric failure to thrive, and the pipeline currently comprises six clinical-stage assets: AMS-1282, AMS-2392, AMS-2572, AMS-3830, AMS-3657, AMS-3469, AMS-4133, and AMS-6731.

The company's technical platform is built on quantitative biology in human subjects using advanced stable isotope tracer methodology combined with kinetic modeling. Its drug design approach pairs modulation of metabolic signaling molecules (including mTORC1) with delivery of the necessary metabolic substrates, with the goal of restoring normal flux through disease-affected pathways. AMS-1282 has received FDA approval to begin a Phase 3 trial in July for HFpEF, and AMS-2392 is in FDA-aligned Phase 3 design for alcoholic fatty liver disease; Phase 2 readouts for AMS-1282 and AMS-3830 and a Phase 1 readout for AMS-2392 are cited as evidence of clinical activity.

Amino Medical Science is pre-revenue and does not yet commercialize products, so its go-to-market model is currently defined by clinical trial execution, scientific publication, and regulatory engagement rather than by established distribution or pricing. The company reports no disclosed institutional funding rounds, no partnerships, and no commercial customers. Its scientific team is described as having authored over 500 peer-reviewed publications and accumulated more than 70,000 citations. Future revenue, when generated, is expected to flow through traditional pharmaceutical distribution channels following FDA approval, with pricing to be set at or after launch.

Name

Amino Medical Science

Legal name

Amino Medical Science, Inc.

Website

https://aminomedicalscience.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Amino Medical Science is a private, clinical-stage biotech developing small molecule therapeutics that combine metabolic substrate delivery with mTORC1 modulation to treat HFpEF, cachexia, obesity, fatty liver disease, and pediatric failure to thrive.

Ownership category

akta.pro rank

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine) (AFAJAKAG)

Keywords

• Small molecule therapeutics
• Metabolic disease treatments
• Clinical-stage biotechnology
• Heart failure therapeutics
• Obesity drug development

Headquarters

HQ city

Lewes

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical stage company. The company is developing a pipeline of therapeutic candidates across multiple therapeutic areas (heart failure, cachexia, obesity, fatty liver disease, failure to thrive). Revenue will be generated through commercialization of FDA-approved pharmaceutical products following successful completion of clinical trials.

Go-to-market motion1 record

Core offering

Amino Medical Science develops a pipeline of clinical-stage small molecule therapeutics that combine metabolic signaling activation with substrate delivery to treat multifactorial diseases. The company's portfolio targets heart failure with preserved ejection fraction (HFpEF), cachexia, obesity, fatty liver disease/PCOS, and pediatric failure to thrive, using stable isotope tracer methodology and kinetic modeling to design therapies that restore normal flux through disease-affected pathways.

Product overview

Amino Medical Science is a biotechnology company developing a portfolio of targeted small molecule therapeutic products. The company uses a novel approach combining metabolic substrate delivery with mRNA translation modulation to treat multifactorial diseases. The product portfolio includes multiple clinical-stage candidates: AMS-1282 (heart failure), AMS-2392 and AMS-2572 (fatty liver disease/PCOS), AMS-3830 and AMS-3469 (obesity/bariatric surgery support), AMS-3657 (hypocaloric protein metabolism), AMS-4133 (cancer cachexia), and AMS-6731 (pediatric growth). These treatments are designed to restore normal metabolic flux by providing both signaling modulation and necessary substrates for targeted reactions.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 100% trial success rate for Phase II and beyond (compared to traditional pharmaceutical rate of less than 10%)
• +3 more outcomes

Segments5 records

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• BridgeBio Pharma: Clinical-stage cardiometabolic/genetics biotech with multiple programs including heart failure and metabolic disease assets. Comparable in multi-asset cardiometabolic pipeline approach, though larger and more diversified.
• Esperion Therapeutics: Commercial-stage cardiometabolic/lipid management company with approved LDL-lowering therapies. Comparable in cardiometabolic therapeutic area overlap (lipid/cardiovascular outcomes), though further commercialized.
• Akcea Therapeutics: Cardiometabolic-focused subsidiary historically developing therapies for lipid disorders and metabolic disease. Comparable in cardiometabolic therapeutic focus, though broader and portfolio-driven.
• Boehringer Ingelheim (Cardiometabolic): Large pharmaceutical incumbent with significant heart failure (e.g., empagliflozin/Jardiance HF franchise) and cardiometabolic programs. Comparable in heart failure/HFpEF therapeutic area, though orders of magnitude larger and commercialized.

Emerging players

• Cardior Pharmaceuticals: European clinical-stage biotech focused on heart failure and cardiac remodeling using RNA-based therapeutics. Comparable as an emerging heart-failure specialist, though on a different modality (RNA vs substrate-based).

Direct peers

• Viking Therapeutics: Clinical-stage metabolic-disease biotech developing VK2735 (oral/obesity) and other cardiometabolic candidates. Directly comparable clinical-stage profile in obesity and metabolic disease.
• Cytokinetics: Clinical-stage cardiovascular biotech developing small-molecule cardiac muscle modulators, including heart failure assets. Directly comparable in therapeutic-area focus (HFpEF/HFrEF) and clinical-stage profile as a small, focused cardiovascular drug developer.
• Intercept Pharmaceuticals: Cardiometabolic/hepatology biotech historically focused on NASH with obeticholic acid. Direct peer in fatty liver/PCOS therapeutic overlap with Amino Medical Science's AMS-2392/AMS-2572.
• Madrigal Pharmaceuticals: Clinical-stage metabolic-disease biotech that received FDA approval for resmetirom (Rezdiffra) in MASH/NASH. Directly comparable in fatty liver disease focus (analogous to AMS-2392) and clinical-stage cardiometabolic profile.
• Lexicon Pharmaceuticals: Clinical-stage cardiometabolic biotech with small-molecule programs in diabetes, obesity, and heart failure. Comparable in therapeutic area breadth and clinical-stage development approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amino Medical Science